|Market Cap||Dividend Yield (Annualized)|
|0.26L 0.27 H|
|52 WEEK HIGH LOW|
|0.13L 0.625 H|
|52 W H/L||0.625/0.130|
|NPAT After Abnormal Items||-18.455M|
|Cash and Cash Equivalents||29.487M|
|Price/Gross Cash Flow||-137.41|
|Dividend Yield Excluding Special||0.00%|
|Gross DPS (AUD)||0|
|Gross Dividend Yield (Annualized)||0.00%|
|Net Tangible Asset (NTA)||0.01|
|Net Profit Margin (%)||--|
|Gross Cash Flows Per Share||-0.00|
|Sales Per Share||0.00|
|Book Value Per Share||0.01|
Imugene Limited (ASX:IMU) is an Australia-headquartered clinical stage immuno-oncology firm which is in the process of developing a wide array of new treatments that attempt to activate the cancer patients’ immune system to detect and remove tumours. The Company intends to improve and transform the lives of cancer-bearing patients who need effective treatments.
Imugene is backed by a leading team of international cancer experts who hold extensive experience in advancing new cancer therapies. The Company’s efficient and strong management team provides confidence in its ability to discover and manage the development and sales process for its products.
The Company’s clinical pipeline comprises multiple immunotherapy B-Cell vaccine candidates and an Oncolytic Virotherapy CF33, which intend to treat a range of cancers along with the standard of care drugs as well as emerging immunotherapies. The B-cell immunotherapies comprise PD1-Vaxx and two HER2 B-cell immunotherapies - HER-Vaxx and B-Vaxx.
PD-1 Vaxx, or the PD-1 B-cell immunotherapy, aims to induce the patient’s body to generate polyclonal antibodies which block PD-1 signalling, and therefore, create an anticancer effect akin to Opdivo, Keytruda and the other immune checkpoint inhibitors, which have transitioned the treatment for a range of cancers. Besides, HER-Vaxx has been designed for treating tumours which over-express the HER-2 protein, like gastric, lung, pancreatic, breast, and ovarian cancers. Akin to HER-Vaxx, B-Vaxx has also been designed for treating tumours which over-express the HER-2 protein.
Acquired by the Company in November 2019, CF33 was developed by renowned Professor Yuman Fong at City of Hope (COH) Cancer Centre based in Los Angeles, California. CF33 is identified as a chimeric vaccinia poxvirus in the area of oncolytic virotherapy that comes in two different forms: CHECKVacc and Vaxinia. Through the use of CF33, Imugene hopes to bolster the clinical benefits and quality of living for patients suffering from cancers that are difficult to treat through current therapeutic approaches.
Level 3, 62 Lygon Street, CARLTON, VIC, AUSTRALIA, 3053
|Ex-Date||Net Dividend||Frank Flag||Period End Date||Type||Payable|
|Event Type||Event Date||Event Year|